Address
Email address
Phone number
https://cellintechnologies.comCell Therapy Company | Cellin TechnologiesContract GMP manufacturing services for aseptically prepared cell therapy medicinal products.
Name
OÜ Cellin Technologies
Registry code
11543666
VAT number
EE101262352
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
30.09.2008 (16)
Financial year
01.01-31.12
Capital
321 758.00 €
Activity
72111 - Research and experimental development on biotechnology
-
-
-
-
-
-
Not submitted
No tax arrears
-
-
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| M.K.K Investeeringute OÜ 11814817 | 2% - 7 702.00 EUR | - | - | |
| aktsiaselts INFO-AUTO 10078598 | 20% - 64 360.00 EUR | - | - | |
| Globalex Europe OÜ 11712175 | 0% - 595.00 EUR | - | - | |
| OÜ Raik ja Pojad 10677436 | 2% - 5 281.00 EUR | - | - | |
| OÜ Syndoc 14108675 | 2% - 4 916.00 EUR | - | - | |
| OÜ Postinvest 14241090 | 12% - 38 839.00 EUR | - | - | |
| OÜ Kesaten Invest 10890584 | 9% - 28 969.00 EUR | - | - | |
| Hollin Invest OÜ 11327218 | 6% - 19 262.00 EUR | - | - | |
| Teddy Invest OÜ 14281617 | 0% - 1 500.00 EUR | - | - | |
| AS Taastava Kirurgia Kliinik 10286204 | 43% - 137 619.00 EUR | - | - | |
| KATAMER OÜ 10907729 | 4% - 12 590.00 EUR | - | - | |
| Anu Aaspõllu 18.04.1961 (63) | 0% - 125.00 EUR | - | - | Founder |
| Ivari Saar 04.05.1985 (39) | - | Board member | Member of a higher management body, i.e. board member or supervisory board member | |
| Tiit Meren 21.06.1955 (69) | - | - | - | Board member |
| Heinu Klaas 10.10.1963 (61) | - | - | - | Board member |
| Andrus Loog 14.08.1963 (61) | - | - | - | Chairman of the board |
| Osaühing ZR Investeeringud 10706712 | - | - | - | Founder |
| Osaühing ProtoBioS 10981915 | - | - | - | Founder |
| BIOINF OÜ 11359595 | - | - | - | Founder |
| OÜ IndiPro 11371231 | - | - | - | Founder |
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Biolaborid OÜ 11879691 | 72% - 82 511.00 EUR | - | - |
| 2019 02.11.2020 | 2020 01.07.2021 | 2021 04.08.2022 | 2022 02.08.2023 | |
|---|---|---|---|---|
| Total Revenue | 8 040 € | 16 580 € | 10 015 € | 17 424 € |
| Net profit (loss) for the period | -476 459 € | -845 808 € | -636 798 € | -613 024 € |
| Profit Margin | -5926% | -5101% | -6358% | -3518% |
| Current Assets | 429 700 € | 15 920 € | 15 175 € | 113 609 € |
| Fixed Assets | 1 356 743 € | 8 183 434 € | 7 844 689 € | 7 509 452 € |
| Total Assets | 1 786 443 € | 8 199 354 € | 7 859 864 € | 7 623 061 € |
| Current Liabilities | 1 692 264 € | 2 045 460 € | 2 394 768 € | 2 012 679 € |
| Non Current Liabilities | 74 152 € | 133 152 € | 141 152 € | 141 152 € |
| Total Liabilities | 1 766 416 € | 2 178 612 € | 2 535 920 € | 2 153 831 € |
| Share Capital | - | - | - | - |
| Equity | 20 027 € | 6 020 742 € | 5 323 944 € | 5 469 230 € |
| Employees | 3 | 3 | 3 | 5 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 624 € | 18 905.37 € | 20 126.06 € | 7 |
| 2023 Q4 | 28 159.67 € | 20 124.74 € | 21 368.04 € | 6 |
| 2023 Q3 | 11 390.84 € | 20 338.91 € | 21 559.3 € | 6 |
| 2023 Q2 | 10 139.64 € | 18 055.58 € | 19 167.75 € | 6 |
| 2023 Q1 | 787.67 € | 20 172.52 € | 21 361.54 € | 7 |
| 2022 Q4 | 15 600 € | 18 563.63 € | 19 748.8 € | 7 |
| 2022 Q3 | 20 357.57 € | 20 033.63 € | 21 375.86 € | 8 |
| 2022 Q2 | 700 € | 12 970.97 € | 13 674.92 € | 8 |
| 2022 Q1 | 2 186 € | 8 344.92 € | 8 666 € | 9 |
| 2021 Q4 | 1 600 € | 9 046.6 € | 9 541.94 € | 4 |
| 2021 Q3 | 2 504 € | 8 997.79 € | 9 371.3 € | 4 |
| 2021 Q2 | 2 342.25 € | 6 139.05 € | 6 450.26 € | 4 |
| 2021 Q1 | 1 882.5 € | 8 378.14 € | 8 743.87 € | 7 |
| 2020 Q4 | 2 193.3 € | 8 349.84 € | 8 665.23 € | 6 |
| 2020 Q3 | 11 710 € | 6 759.84 € | 7 075.23 € | 6 |
| 2020 Q2 | 2 677 € | 5 246.88 € | 5 465.86 € | 6 |
| 2020 Q1 | - | 11 354.87 € | 11 669.72 € | 6 |
